United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.01, for a total transaction of $5,006,595.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $21,350,756.13. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Up 1.8%

United Therapeutics stock opened at $541.60 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $549.50. The company’s 50 day moving average price is $493.58 and its two-hundred day moving average price is $471.33. The stock has a market cap of $23.74 billion, a P/E ratio of 19.41, a P/E/G ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $6.19 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $549.91.

Institutional Trading of United Therapeutics

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. purchased a new stake in United Therapeutics in the 3rd quarter worth about $317,617,000. Norges Bank bought a new stake in United Therapeutics in the 4th quarter valued at about $293,418,000. Invesco Ltd. raised its stake in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the period. Finally, Avoro Capital Advisors LLC lifted its holdings in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
• Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
• Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
• Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
• Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
• Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.